LUND, Sweden, Dec. 17, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced positive full results from the 15-HMedIdeS-09 single arm Phase 2 study of imlifidase, a ...
ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...
Annexon, Inc. presented promising findings regarding its investigational therapy tanruprubart at the 2025 Peripheral Nerve Society Annual Meeting. The oral presentation highlighted the benefits of ...
Guillain-Barré Syndrome (GBS) is a rare autoimmune condition where the the peripheral nervous system becomes a target of the ...
Guillain-Barré Syndrome (GBS) is a rare neuromuscular condition that can cause rapid paralysis. Diagnosing GBS is challenging, and misdiagnosis can lead to delayed treatment and potentially long-term ...
MUMBAI: The tally of Guillain Barre Syndrome (GBS) cases in Maharashtra has reached 189, while the first GBS-suspected patient from Andheri-East was detected on Friday. Mumbai's first GBS patient is a ...
Barré syndrome market is poised for substantial growth, fueled by advancements in treatment options, including intravenous immunoglobulin (IVIg), plasmapheresis, and emerging immunotherapies.
BRISBANE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with ...
Patients with Guillain- Barré syndrome (GBS) face a rare and heterogeneous disorder of the peripheral nervous system that is often triggered by preceding infections and causes severe muscle weakness.
The risk for Guillain-Barré syndrome (GBS) is six times higher in people with COVID-19 in the 6 weeks following infection, according to a new study that also showed receipt of the Pfizer-BioNTech mRNA ...
KYOTO, Japan — Eculizumab (Soliris, Alexion Pharmaceuticals) is safe for the treatment of patients with severe Guillain-Barré syndrome (GBS), a new phase 2 study shows. However, although more patients ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback